Amendments to the Claims

Claims 1 to 34 have been canceled.

35. (Currently amended) A ~~The~~ method of inducing a T_H1 polarized immune response to an antigen, comprising parenterally administering to a subject microparticles sized such that ~~of Claim 1, wherein the microparticles are sized such that~~ the average diameter of the microparticles is from about 2.2 μm to about 4.3 μm.

36. (Previously presented) The method of Claim 35, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

37. (Previously presented) The method of Claim 35, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

38. (Previously presented) The method of Claim 35, wherein the microparticles are formed using a solvent evaporation method.

39. (Previously presented) The method of Claim 35, wherein the antigen comprises a *B. pertussis* antigen.

40. (Previously presented) The method of Claim 35, wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.

41. (Currently amended) A ~~The~~ vaccine formulation for enhancing the T_H1 immune response to at least one antigen and adapted for parenteral administration comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of

microparticles sized such that ~~of Claim 15, wherein the microparticles are sized such that~~ the average diameter of the microparticles is from about 2.2 μm to about 4.3 μm.

42. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are sized such that at least 50% of the microparticles are less than 3 μm.

43. (Previously presented) The vaccine formulation of Claim 41, wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.

44. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles are formed using a solvent evaporation method.

45. (Previously presented) The vaccine formulation of Claim 41, wherein the antigen comprises a *B. pertussis* antigen.

46. (Previously presented) The vaccine formulation of Claim 41, wherein the microparticles comprise at least 2 subpopulations of microparticles, each subpopulation comprising a different antigen entrapped or encapsulated by a biodegradable polymer.